Current and Emerging Treatments for Myelodysplastic Syndromes: The 2021 Landscape

How would you risk stratify this patient?

Submit

Which of these mutations is considered “good risk” in MDS?

Submit

Which of these mutations is considered “poor risk” in MDS?

Submit

What is the likelihood of response to erythropoiesis stimulating agents (epo, darbe)?

Submit

What is the likelihood to response to lenalidomide for del(5q) MDS?

Submit

What treatment option do you recommend for this patient?

Submit

Based on the data presented, what treatment option would you now recommend for this patient?

Submit